UL Solutions Inc. (ULS)
ULS trades on NYSE in Health Care, Precision Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$71.08
-0.14% on the day
Market cap
$14.4B
Large cap
Revenue · 2025
$3.1B
+6.4% on 2024
Net income · 2025
$325.0M
10.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ULS on NYSE |
| Sector | Health Care |
| Industry | Precision Instruments |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001901440 |
| SEC industry code | Services-Testing Laboratories |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.1B |
| Net income | $325.0M |
| Operating income | $522.0M |
| Net margin | 10.6% |
| Operating margin | 17.1% |
| Revenue growth | +6.4% |
| Cash | $295.0M |
| Total assets | $2.9B |
| P/E (computed) | 44.2× |
| P/S (computed) | 4.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2025-12-05 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-10-01 |
| Latest proxy | DEFA14A | 2026-04-02 |
Source: SEC EDGAR submissions feed, 556 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.3% |
| 1 month | +10.2% |
| 3 months | -20.4% |
| Year to date | -9.5% |
| 1 year | -1.4% |
| From 52-week high | -32.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Precision Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NEO | NeoGenomics Inc. | $16.66 | +2.84% | $2.1B |
| AIDX | 20/20 Biolabs Inc. | $0.3513 | -4.02% | $4.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier